Interventional × Neoplasms by Histologic Type × Other hematologic neoplasm × Clear all
NCT04904588 2026-03-18

ACCESS

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
300 enrolled
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA